TEOSYAL® PURESENSE REDENSITY II
Firstly, Teosyal® PureSense Redensity II is an advanced gel designed to treat the delicate and sensitive eye area. The product has a subtle mix of non cross-linked and cross-linked hyaluronic acid that is specifically indicated for under-eye circles and hollow eye-circles. The ingredients in Teosyal® PureSense Redensity II helps to regenerate and restructure skin cells, while it protects the cells from oxidation. This improves the quality of the skin and provides a natural and long-lasting correction of tired looking eyes. TEOSYAL® PURESENSE REDENSITY II
Please be aware that the product cannot be used to treat sunken under-eye circles and malar bags.
Buy other Teosyal products here
Secondly, The pack consists of:
2 x 1 ml syringes
2 x 30G ½ needles
15 mg/ml Hyaluronic Acid
8 Amino acids – Arginine, Glycine, Isoleucine, Leucine, Lysine, Proline, Threonine and Valine
3 Antioxidants – Alphalipoic Acid, Glutathion and N-acetyl-L-cysteine
2 Minerals – Copper and Zinc
Teosyal® PureSense Redensity II contains Lidocaine, which minimizes the pain and ensure a more comfortable treatment for the patient.
Thirdly, Benefits of Teosyal® PureSense Redensity II:
Areas: The delicate and sensitive eye area
Treat under-eye circles and hollow eye-circles
Also designed for tear trough treatment
How long does the result last for?
In general, results can last up to 9-12 months. The duration depends on the individual’s lifestyle, age and skin type.
Also, FLEXCARE MEDICAL B.V is a trusted online shop of aesthetic products and medical devices from the most popular brands on the market. We offer a wide range of different fillers and professional skincare products to clinics and hospitals worldwide. We strive to be your preferred online supplier of aesthetic products and to suit the needs of your business. In addition, we guarantee competitive prices, fast delivery and accessible & friendly customer service in our online chat.
THE ORIGIN OF THIS PRODUCT IS FROM THE EUROPEAN COMMUNITY (EC)
There are no reviews yet.